REGENERON PHARMACEUTICALS, INC. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2010 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Regeneron Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2010 to Q2 2024.
  • Regeneron Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was $1.43B, a 47.9% increase year-over-year.
  • Regeneron Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was $4.32B, a 0.53% increase year-over-year.
  • Regeneron Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was $3.95B, a 8.87% decline from 2022.
  • Regeneron Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was $4.34B, a 46.3% decline from 2021.
  • Regeneron Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was $8.08B, a 130% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $4.32B $1.43B +$464M +47.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 $3.86B $722M -$95.8M -11.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-01
Q4 2023 $3.95B $1.16B -$37.5M -3.13% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-05
Q3 2023 $3.99B $1.01B -$308M -23.4% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-02
Q2 2023 $4.3B $968M +$116M +13.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 $4.18B $818M -$156M -16% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-01
Q4 2022 $4.34B $1.2B -$1.03B -46.3% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-05
Q3 2022 $5.37B $1.32B -$317M -19.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $5.69B $852M -$2.25B -72.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-02
Q1 2022 $7.93B $974M -$142M -12.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-02
Q4 2021 $8.08B $2.23B +$1.08B +94% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-05
Q3 2021 $7B $1.63B +$790M +93.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $6.21B $3.1B +$2.2B +245% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-03
Q1 2021 $4B $1.12B +$491M +78.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-03
Q4 2020 $3.51B $1.15B +$357M +45.1% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-08
Q3 2020 $3.16B $842M +$173M +25.8% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $2.98B $897M +$704M +365% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-04
Q1 2020 $2.28B $625M +$164M +35.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-04
Q4 2019 $2.12B $792M -$28.4M -3.46% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-08
Q3 2019 $2.14B $670M +$74.9M +12.6% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-08
Q2 2019 $2.07B $193M -$358M -65% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-08
Q1 2019 $2.43B $461M -$16.9M -3.54% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-08
Q4 2018 $2.44B $820M +$647M +373% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-07
Q3 2018 $1.8B $595M +$206M +53.2% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-07
Q2 2018 $1.59B $551M +$164M +42.2% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-07
Q1 2018 $1.43B $478M +$229M +92% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-07
Q4 2017 $1.2B $174M -$79.6M -31.5% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-07
Q3 2017 $1.28B $388M +$123M +46.6% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-07
Q2 2017 $1.15B $388M +$191M +97.6% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-07
Q1 2017 $963M $249M +$67.5M +37.2% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-07
Q4 2016 $896M $253M +$98.1M +63.3% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-08
Q3 2016 $797M $265M +$54.4M +25.9% Jul 1, 2016 Sep 30, 2016 10-K 2018-02-08
Q2 2016 $743M $196M +$1.58M +0.81% Apr 1, 2016 Jun 30, 2016 10-K 2018-02-08
Q1 2016 $741M $181M +$105M +139% Jan 1, 2016 Mar 31, 2016 10-K 2018-02-08
Q4 2015 $636M $155M +$64.9M +72% Oct 1, 2015 Dec 31, 2015 10-K 2017-02-09
Q3 2015 $571M $210M +$127M +152% Jul 1, 2015 Sep 30, 2015 10-K 2017-02-09
Q2 2015 $444M $195M +$98.3M +102% Apr 1, 2015 Jun 30, 2015 10-K 2017-02-09
Q1 2015 $346M $76M +$7.72M +11.3% Jan 1, 2015 Mar 31, 2015 10-K 2017-02-09
Q4 2014 $338M $90.1M -$6.71M -6.93% Oct 1, 2014 Dec 31, 2014 10-K 2016-02-11
Q3 2014 $345M $83.4M -$57.9M -41% Jul 1, 2014 Sep 30, 2014 10-K 2016-02-11
Q2 2014 $403M $96.4M +$8.98M +10.3% Apr 1, 2014 Jun 30, 2014 10-K 2016-02-11
Q1 2014 $394M $68.3M -$30.6M -30.9% Jan 1, 2014 Mar 31, 2014 10-K 2016-02-11
Q4 2013 $424M $96.8M -$374M -79.4% Oct 1, 2013 Dec 31, 2013 10-K 2015-02-12
Q3 2013 $798M $141M -$50.2M -26.2% Jul 1, 2013 Sep 30, 2013 10-K 2015-02-12
Q2 2013 $848M $87.4M +$10.6M +13.9% Apr 1, 2013 Jun 30, 2013 10-K 2015-02-12
Q1 2013 $837M $98.9M +$87.2M +749% Jan 1, 2013 Mar 31, 2013 10-K 2015-02-12
Q4 2012 $750M $470M +$524M Oct 1, 2012 Dec 31, 2012 10-K 2014-02-13
Q3 2012 $226M $191M +$254M Jul 1, 2012 Sep 30, 2012 10-K 2014-02-13
Q2 2012 -$27.4M $76.7M +$139M Apr 1, 2012 Jun 30, 2012 10-K 2014-02-13
Q1 2012 -$167M $11.7M +$55.1M Jan 1, 2012 Mar 31, 2012 10-K 2014-02-13
Q4 2011 -$222M -$53.4M -$38.8M -266% Oct 1, 2011 Dec 31, 2011 10-K 2013-02-15
Q3 2011 -$183M -$62.4M -$28.5M -84.1% Jul 1, 2011 Sep 30, 2011 10-K 2013-02-15
Q2 2011 -$154M -$62.5M -$37M -145% Apr 1, 2011 Jun 30, 2011 10-K 2013-02-15
Q1 2011 -$117M -$43.4M -$12.9M -42.3% Jan 1, 2011 Mar 31, 2011 10-K 2013-02-15
Q4 2010 -$104M -$14.6M Oct 1, 2010 Dec 31, 2010 10-K 2012-02-21
Q3 2010 -$33.9M Jul 1, 2010 Sep 30, 2010 10-K 2012-02-21
Q2 2010 -$25.5M Apr 1, 2010 Jun 30, 2010 10-K 2012-02-21
Q1 2010 -$30.5M Jan 1, 2010 Mar 31, 2010 10-K 2012-02-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.